An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Taysha Gene Therapies (NASDAQ: TSHA) announced it will report third-quarter financial results on November 10, 2021, at 8:00 AM Eastern Time. The company is focused on developing AAV-based gene therapies for central nervous system diseases, aiming to provide curative treatments for both rare and larger patient populations. The conference will include a corporate update and access to a webcast will be available for 30 days post-event.
Positive
Focused on developing AAV-based gene therapies for CNS diseases.
Conference call for corporate update shows transparency with investors.
Negative
None.
DALLAS--(BUSINESS WIRE)--
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the third quarter ended September 30, 2021, and host a corporate update conference call and webcast on Wednesday, November 10, 2021, at 8:00 AM Eastern Time.
Conference Call Details
Wednesday, November 10, at 8:00 AM Eastern Time / 7:00 AM Central Time
An archived version of the webcast will be available on Taysha’s website for 30 days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
